source
- Eli Lilly reports strongest weight-loss data yet; Sanofi and Regeneron secure $1 billion upfront dealThe weekly Endpoints newsletter dated October 3, 2026 highlights that Eli Lilly's latest weight‑loss trial produced its best‑ever results. While the article does not provide specific numbers, the…
- BMO sees Merck better positioned than BMS to handle looming patent cliffsBMO Capital Markets says Merck has a stronger plan than Bristol Myers Squibb to replace revenue lost to upcoming patent expirations. The firm highlights Merck's pipeline as more derisked and sizabl…